JRCT ID: jRCT2042240074
Registered date:20/08/2024
A validation study of the voice-based cognitive assessment program
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Healthy adults, Suspected cognitive decline.Picking up undiagnosed or untreated patients at fam |
Date of first enrollment | 20/08/2024 |
Target sample size | 99 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | Using this device, cognitive function tests and psychological tests (MoCA-j, CDR, MMSE-J) will be conducted by recording spoken voice, and the test results will be compared. |
Outcome(s)
Primary Outcome | To evaluate the MoCA-J score, sensitivity and specificity of this device for definitive diagnosis results |
---|---|
Secondary Outcome | The correlation between the test results of this device and the CDR Global Score and MMSE-J score will be evaluated. |
Key inclusion & exclusion criteria
Age minimum | >= 50age old |
---|---|
Age maximum | < 90age old |
Gender | Both |
Include criteria | 1. Subjects aged 50 to 90 years old who meet the following criteria (1), (2), or (3). (1)Dementia (already diagnosed) (2) Suspected cognitive decline (3) Healthy adults 2.Able to take a medical interview (conversation with a doctor or medical professional). 3. Able to be accompanied by a co-participant (study partner) who can answer the CDR. 4.Who can obtain written consent from the person or his / her substitute or study partner. |
Exclude criteria | 1.Those who have been judged by a doctor to have difficulty speaking normally. 2. Who has been diagnosis with a psychiatric disorder such as depression. 3. Meets any of the following criteria (1), (2), or (3). (1)Dementia (diagnosed) Who has undergone neuropsychological examination within last 3 months. (2)Suspected cognitive decline Who has undergone neuropsychological examination within last 6 months. (3)Healthy adult Who has undergone neuropsychological examination within last 6 months. 4.Who has been judged by a doctor that suspected to have a sevier respiratory disease. 5.Who has confirmed participate of development of this AI system. 6.Who has been judged by a doctor not to be suitable for this study by any reasons. |
Related Information
Primary Sponsor | Tobita kimimasa |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | SEKISUI CHEMICAL CO., LTD |
Secondary ID(s) |
Contact
Public contact | |
Name | Clinical trial contact |
Address | 338 Kokusai Building, 1-1 Marunouchi 3-chome, Chiyoda-ku tokyo Tokyo Japan 100-0005 |
Telephone | +81-3-6810-2130 |
clinical_study@dm-partners.jp | |
Affiliation | Dream Medical Partners Co., Ltd. |
Scientific contact | |
Name | kimimasa Tobita |
Address | 338 Kokusai Building, 1-1 Marunouchi 3-chome, Chiyoda-ku tokyo Tokyo Japan 100-0005 |
Telephone | +81-3-6810-2130 |
clinical_study@dm-partners.jp | |
Affiliation | Dream Medical Partners Co., Ltd. |